Aperam


FY23 in line; some hopes for recovery (H2 24)?

12/02/24 -"The group released an expected set of results, while it also anticipates a rather similar Q1 24 vs Q3 23. Even if the market is still depressed, particularly in Europe, a stabilisation is welcome and ..."

Pages
62
Language
English
Published on
12/02/24
You may also be interested by these reports :
23/02/24
There were no real surprises in the FY23 results. Market conditions were tough, with depressed prices across the board. The H124 will remain weak ...

23/02/24
The context for materially weak 2023 results was set in late-2023, when the management acknowledged various (production) issues. While these numbers ...

23/02/24
Glencore’s 2023 results were much lower vs. an extraordinary 2022. Moreover, dividends were slashed materially also considering the bet on Teck’s met ...

22/02/24
The FY23 results were better than the market’s expectations. More importantly, the outlook looks positive. FY24 will be lower than the previous ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO